Search
Search
Generating stable clones involves variability across transfection, selection, and screening that can extend timelines and delay manufacturing readiness. Differences in media, vector design, and selection strategy may shift productivity before processes reach scale. Stable cell line development kits address this complexity by integrating host cell lines, expression vectors, media, and reagents into coordinated systems that promote consistent workflows from cloning through stable pool generation. By aligning components evaluated together, these kits streamline clone screening and enable a smoother handoff into process development and scale-up.
The Gibco CHOvantage GS Cell Line Development Kit is a GS-based CHO-K1 cell line development platform designed to support stable expression, high titer, and sustained productivity across passages. Its transposon-based vector system enables efficient gene integration. It can generate stable pools with monoclonal antibody (mAb) titers greater than or equal to 7 g/L in fed-batch evaluations. In development studies, selected clones maintained productivity for up to 100 generations.
Optimized for use with Gibco Efficient-Pro Medium (+) Insulin, Gibco Efficient-Pro Feed 3, and Gibco Efficient-Pro Feed Enhancer—all included in the kit—the kit enables insulin-dependent CHO-K1 GS lines to achieve high cell densities while sustaining protein expression throughout process development.
For teams requiring alternative host cell backgrounds, Gibco Freedom Cell Line Development Kits, including ExpiCHO-S, CHO-S, and DG44, support multiple host cell backgrounds and selection systems for cloning and protein expression. These kits contain animal origin–free (AOF) media formulations and offer flexibility in selection strategies across development programs.
Kit selection depends on host cell background, selection strategy, workflow preferences, and downstream manufacturing goals.
CHO-K1 lines enable rapid growth and high productivity for fed-batch mAb production. CHO-S lines adapt to suspension and serum-free workflows. DG44 lines enable methotrexate-based amplification to increase gene copy numbers and expression.
GS and puromycin systems allow direct selection without amplification, while DHFR-null systems require methotrexate titration. Teams should weigh timelines, productivity targets, and scalability when choosing between rapid pool generation and amplification strategies.
Table 1. Comparison of Gibco Stable Cell Line Development Kits
| Cell line development kit | Host cell line | Selection system | Primary application |
| CHOvantage GS Kit | CHO-K1 | Glutamine synthetase | mAb production and mAb variants |
| Gibco Freedom ExpiCHO-S Kit | ExpiCHO-S | Puromycin | mAb and recombinant protein |
| Gibco Freedom CHO-S Kit | CHO-S | Puromycin | mAb production |
| Gibco Freedom DG44 Kit | DG44 | Methotrexate/DHFR | mAb and recombinant protein |
Cell culture products, including media, functional additives, feeds, and supplements, work alongside stable cell line development to maintain productivity and enable efficient scale-up as processes advance from clone selection into manufacturing.
Stable cell line development kits typically include host cell lines, expression vectors, reagents, and optimized media formulations paired to work together. Some kits also offer transfection reagents, protocols, and quality documentation to support development workflows. Components are selected to enable consistent transfection, stable integration, and clone selection without requiring teams to source individual materials separately.
Host cell background influences growth characteristics, selection marker compatibility, and downstream process suitability. CHO-K1 lines grow rapidly and enable high productivity in fed-batch culture. CHO-S lines support consistent growth and protein expression in scalable culture systems. DG44 lines lack functional DHFR, enabling methotrexate-based amplification to increase gene copy number and protein expression. Kit design reflects these differences, pairing each host cell line with compatible vectors, selection strategies, and media formulations.
Complete kits for cell line development enable coordinated components across transfection, selection, and culture stages. Teams working with unfamiliar cell lines or selection systems may benefit from kits that streamline workflow setup and reduce the need to optimize individual reagent combinations. Kits also allow faster project initiation when timelines favor standardized approaches over custom component sourcing, particularly during early-phase development. Integrated platforms can also help reduce qualification burden and simplify material sourcing during early-phase development.
Stable cell line development kits are designed to align with downstream processing (DSP) requirements by using host cell lines and media formulations that scale into manufacturing workflows. cGMP-banked cell lines, regulatory documentation, and media compatibility with larger bioreactor systems support smoother handoffs from clone selection into process characterization and scale-up, helping reduce re-optimization.
Kits typically include quality documentation, such as certificates of analysis (CoA), raw material traceability, and manufacturing records, that support regulatory submissions. cGMP-banked cell lines offer documented lineage and testing records. Media and reagent lots include specification sheets and stability data. This documentation helps teams meet process development and qualification requirements during early-stage development and technology transfer activities.
Gibco stable cell line development kits offer royalty-free commercial licensing. Teams evaluating cell line development platforms should review applicable licensing terms during early process planning to align with long-term manufacturing and commercialization strategies.
For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.